At a glance
Effects
- Tissue & tendon repair: BPC-157 and TB-500 stimulate fibroblast migration and angiogenesis, reported to accelerate healing of muscle, tendon, ligament, and gut lining in animal models [6][7].
- Anti-inflammatory action: KPV inhibits NF-κB at nanomolar concentrations, reducing pro-inflammatory cytokines; BPC-157 also attenuates oxidative and inflammatory injury [6][3].
- Collagen & skin rejuvenation: GHK-Cu stimulates collagen and elastin production, smooths skin texture, and supports connective-tissue remodelling; GHK-Cu levels decline from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 [8][4].
- Gut lining protection: BPC-157 and KPV together support mucosal integrity, gastrointestinal barrier function, and may reduce severity of GI inflammatory conditions [3][9].
- Accelerated post-exercise recovery: The TB-500 + BPC-157 pairing is widely reported in athletics and research circles to reduce recovery time after intense training or overuse injuries [7][9].
- Skin elasticity during weight loss: GHK-Cu's collagen-support role is commonly cited in protocols combining KLOW with GLP-1 agonists to preserve skin integrity during rapid fat loss [8].
Compounded multi-peptide injectable blend (GHK-Cu + BPC-157 + TB-500 + KPV)
80 mg lyophilised powder (GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg)
Subcutaneous injection (reconstituted with bacteriostatic water)
Not FDA-approved; BPC-157 & TB-500 banned by WADA (S0 category)
None for the blend; components studied mainly in animal/in vitro models
About KLOW
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
KLOW is a compounded, multi-peptide injectable blend combining four bioactive compounds — GHK-Cu (copper tripeptide-1), BPC-157, TB-500, and KPV — in a single lyophilised vial [1][2]. It is marketed for tissue repair, anti-inflammatory support, collagen synthesis, skin rejuvenation, and accelerated recovery, primarily in wellness, sports-recovery, and aesthetic medicine contexts [3][4].
How it works
Each of the four peptides targets a distinct, complementary step in the healing cascade, and they are designed to act synergistically [5]. BPC-157 activates focal-adhesion kinase (FAK) and VEGF/nitric-oxide signalling to accelerate angiogenesis and fibroblast-driven tissue repair [6]. TB-500 binds G-actin via its LKKTET sequence to drive cell migration, cytoskeletal remodelling, and organised tissue rebuilding with minimal scar formation [5][7]. KPV (an α-MSH tripeptide fragment) competitively blocks NF-κB nuclear translocation at nanomolar concentrations, suppressing pro-inflammatory cytokines without hormonal side effects [6]. GHK-Cu (copper tripeptide-1) modulates TGF-β, SMAD, and MMP signalling to stimulate collagen, elastin, and glycosaminoglycan synthesis and is estimated to influence expression of more than 4,000 genes [6][8]. Together they aim to create a full-spectrum regenerative environment covering angiogenesis, inflammation control, cell migration, and structural remodelling [5].
Risks & side effects
Most important: No human randomised controlled trials have been published for the KLOW blend as a whole, and its individual components (BPC-157 and TB-500) lack FDA approval for any therapeutic indication [10][11]. Unregulated peptide vials sourced outside licensed compounding pharmacies may contain endotoxins, microbial agents, or mis-sequenced peptide chains, and long-term safety in humans has not been established [11].
Common
Serious
- Infection risk from non-sterile preparation or improper injection technique [3]
- Unknown long-term systemic effects — no chronic-use human safety data exist [11]
- Possible tumour-growth promotion risk with GHK-Cu at supraphysiological levels (theoretical; not confirmed in human studies) [6]
- WADA anti-doping violation: BPC-157 and TB-500 are prohibited under S0 (non-approved substances); a Canadian athlete received a 4-year ban [12][13]
Safety & harm reduction
- Competitive athletes subject to WADA or equivalent anti-doping testing — BPC-157 and TB-500 are prohibited substances (S0 category); violations carry multi-year bans [12][13]
- U.S. military service members — BPC-157 is explicitly listed as prohibited by the DoD Operation Supplement Safety (OPSS) programme [14]
- Pregnancy and breastfeeding — no safety data exist [3]
- Individuals with active malignancy — theoretical concern that growth-promoting peptides may accelerate tumour growth [6]
- Known hypersensitivity to any component peptide or copper compounds [3]
- Injection-site inspection at each dose for signs of infection (redness, swelling, warmth, discharge)
- Baseline and periodic liver/kidney function panels if used for extended protocols (no formal guidance exists; advisable given absence of long-term data) [3]
- Blood pressure monitoring — BPC-157 modulates nitric oxide pathways which may affect vascular tone [6]
- Skin and connective-tissue response assessment every 4–8 weeks to gauge benefit and detect unexpected reactions
- Anticoagulants / blood thinners — TB-500's angiogenic activity could theoretically amplify bleeding risk [7]
- Immunosuppressive drugs — KPV modulates NF-κB and immune signalling; additive or antagonistic effects are unknown [6]
- GLP-1 / GIP receptor agonists (e.g. Retatrutide, Semaglutide) — widely co-administered in commercial protocols; no interaction data; GI side effects may compound [8]
- Other growth-factor peptides (e.g. IGF-1 analogues, GHRPs) — cumulative tissue-proliferative effects are uncharacterised [11]
- Reconstitute with 2 mL bacteriostatic water per 80 mg vial for a nominal 40 mg/mL solution; use immediately or store refrigerated and use within the stability window specified by the dispensing pharmacy [9]
- Rotate injection sites (abdomen, thigh) to minimise local tissue reactions [3]
- Use only pharmacy-compounded preparations sourced from licensed 503A compounding pharmacies to reduce contamination risk; research-grade vials sold 'not for human consumption' carry significantly higher purity uncertainty [11]
- Obtain a prescription from a licensed provider before use; self-administration of non-pharmacy-grade peptides carries unquantified safety risk [3][11]
- If pursuing athletic performance recovery, confirm anti-doping status with your governing body before initiating — both BPC-157 and TB-500 trigger WADA S0 violations [12][13]
Dosage context
No FDA-approved or clinically validated dosing protocol exists for KLOW as a blend [10]. A commonly cited community protocol (not a prescription) reconstitutes the 80 mg vial in 2 mL bacteriostatic water (40 mg/mL) and administers 0.1 mL (4 mg of blend) daily via subcutaneous injection, delivering approximately 2.5 mg GHK-Cu, 0.5 mg BPC-157, 0.5 mg TB-500, and 0.5 mg KPV per dose [9]. One wellness source describes a phased schedule: daily for weeks 1–4, five times weekly for weeks 5–8, then two to three times weekly for maintenance [4]. These figures are commonly reported by practitioners and community sources only — individual dosing must be determined by a licensed healthcare provider.
Sources
- 1.EllieMD – KLOW Injection Product Page
- 2.PrimeLab Peptides – KLOW 80mg Product
- 3.Superpower.com – GLOW/KLOW Compounded Injectable Guide
- 4.PeptideFox – GLOW & KLOW Protocol Guide
- 5.Revolution Health – KLOW Peptide Blend Healing & Regeneration
- 6.Cenex Labs – KLOW Blend Peptide (mechanism detail)
- 7.Dr K Conrad – Klow Peptide Blend: Benefits, Dosage, Side Effects
- 8.RedFox Peptides – Retatrutide + KLOW Protocol Results 2026
- 9.Geared Coaching – Deconstructing the Klow Stack
- 10.USADA – BPC-157: Experimental Peptide Creates Risk for Athletes
- 11.BSCG – TB-500: Status, Risks and Bans in Sport and Military
- 12.BSCG – BPC-157: Rules and Risks for Athletes and Military
- 13.Swolverine – Is BPC-157 Legal? WADA, FDA Status
- 14.PubMed/PMC – BPC 157 Multifunctionality Review (NIH)
- 15.Secret MedSpa – Regenerative Healing with KLOW Peptide
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.